Atsuta Y, Hirakawa A, Nakasone H, Kurosawa S, Oshima K, Sakai R, Ohashi K, Takahashi S, Mori T, Ozawa Y, Fukuda T, Kanamori H, Morishima Y, Kato K, Yabe H, Sakamaki H, Taniguchi S, Yamashita T: Late Effect and Quality of Life Working Group of the Japan Society for Hematopoietic Cell. Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant, 22: 1702-9, 2016.
Fujimaki K, Miyashita K, Kawasaki R, Tomita N: Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes. Eur J Haematol, 97: 228-223, 2016.
Hagihara M, Iriyama N, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
Oncol Rep. 36:2976-2982,2016.
Ishii Y, Itabashi M, Numata A, Yamamoto W, Motohashi K, Hagihara M, Matsumoto K, Fujisawa S: Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient. Intern Med, 55: 673-5, 2016.
Ishii Y, Hagihara M, Kato A, Ando T, Itabashi M, Koyama S, Yamamoto W, Motohashi K, Matsumoto K, Fujisawa S: Musculoskeletal pain may be associated with imatinib withdrawal syndrome in chronic myeloid leukemia patients. Leuk Lymphoma, 57: 496-497, 2016.
Matsumoto R, Numata K, Doba N, Hara K, Chuma M, Fukuda H, Nozaki A, Tanaka K, Ishii Y, Maeda S: A case of multiple hepatic lesions associated with methotrexate-associated lymphoproliferative disorder. J Med Ultrason, 43: 545-51, 2016.
Miyashita K, Tomita N, Taguri M, Suzuki T, Ishiyama Y, Ishii Y, Nakajima Y, Numata A, Hattori Y, Yamamoto W, Miyazaki T, Tachibana T, Takasaki H, Matsumoto K, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y: Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy. Leuk Res, 29: 1187-1191, 2016.
Morishita S, Hagihara M, Itabashi M, Ishii Y, Yamamoto W, Numata A, Motohashi K, Matsumoto K, Fujisawa S, Nakajima H: Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia. Rinsho Ketsueki, 57: 999-1003, 2016.
Numata A, Fujisawa S, Itabashi M, Ishii Y, Yamamoto W, Motohashi K, Matsumoto K, Hagihara M, Nakajima H: Favorable prognosis in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia patients following hematopoietic stem cell transplantation. Clin Transplant, 30: 485-6, 2016.
Numata A, Kajiyama R, Itabashi M, Ishii Y, Yamamoto W, Motohashi K, Matsumoto K, Hagihara M, Ishigatsubo Y, Fujisawa S: Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation. Leuk Lymphoma, 57: 201-202, 2016.
Sakai R, Taguri M, Oshima K, Mori T, Ago H, Adachi S, Morita S, Taniguchi S, Fukuda T, Ohashi K, Eto T, Miyamura K, Iwato K, Kobayashi N, Kanamori H, Morishima Y, Nagamura-Inoue T, Sakamaki H, Atsuta Y, Murata M: A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey. Int J Hematol, 103: 322-33, 2016.
Tamura K, Kawai Y, Kiguchi T, Okamoto M, Kaneko M, Maemondo M, Gemba K, Fujimaki K, Kirito K, Goto T1, Fujisaki T, Takeda K, Nakajima A, Ueda T. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi?center trial comparing febuxostat and allopurinol. Int J Clin Oncol, 21: 996?1003, 2016.
Tomita N, Suzuki T, Miyashita K, Yamamoto W, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Taguchi J, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Kawamoto K, Sone H, Takizawa J: The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma. Leuk Lymphoma, 57: 2763-2770, 2016.
Tomita N, Suzuki T, Miyashita K, Yamamoto W, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Taguchi J, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Kawamoto K, Sone H, Takizawa J: The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma. Leuk Lymphoma, 57: 2763-2770, 2016.
Yamamoto W, Andou T, Itabashi M, Koyama S, Ishii Y, Numata A, Motohashi K, Hagihara M, Matsumoto K, Fujisawa S: Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis. Intern Med, 55: 1721-7, 2016.
Yamamoto W, Fujii E, Matsumoto K, Yamamoto E, Aoki J, Tanaka M, Ishigatsubo Y, Kanamori H: Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Int J Hematol,, 103: 444-452, 2016.
Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H: Retrospective Study of Incidence and Prognostic Significance of Eosinophilia after Allogeneic Hematopoietic Stem Cell Transplantation: Influence of Corticosteroid Therapy. Turk J Haematol, 33: 196-201, 2016.
Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H: Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet, 48: 569-574, 2016.
